Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A. Konstantinopoulos, Su–Chun Cheng, Jeffrey G. Supko, Madeline Polak, Andrea E. Wahner-Hendrickson, S. Percy Ivy, Brittany Bowes, Hannah Sawyer, Patrice Basada, Martin Hayes, Jennifer Curtis, Neil S. Horowitz, Alexi A. Wright, Susana M. Campos, Elena V. Ivanova, Cloud P. Paweletz, Sangeetha Palakurthi, Joyce F. Liu, Alan D. D’Andrea, Prafulla C. Gokhale, Dipanjan Chowdhury, Ursula A. Matulonis, Geoffrey I. Shapiro
Topics & Concepts
OlaparibTolerabilityPARP inhibitorMedicinePharmacokineticsSynthetic lethalityOvarian cancerPharmacologyOncologyCancer researchInternal medicineAdverse effectCancerBiologyPoly ADP ribose polymeraseDNA repairBiochemistryGenePolymerasePARP inhibition in cancer therapyHeat shock proteins researchDNA Repair Mechanisms